Neuroblastoma (NB) Market Insights, Epidemiology and Market Forecast till 2023
Neuroblastoma (NB) Market Insights, Epidemiology and Market Forecast 2023 Report will provide an overview of the disease and global market size of the Neuroblastoma (NB) with historical and foretasted epidemiological data for the prevalent cases of Neuroblastoma (NB) from 2013 to 2023.
October 4, 2017 /MarketersMedia/ —
Diligent Market is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, Diligent Market provides cutting-edge data on Neuroblastoma (NB) market and pipeline analysis and API intelligence, helping clients to quantify Neuroblastoma (NB) market events and evaluate their impact on the valuation of its products, portfolios and companies.
Neuroblastoma is an extracranial cancer that starts in certain very early forms of nerve cells found in an embryo or fetus. This type of cancer occurs most often in infants and young children and arises in sympathetic nervous system from neuroblasts. It is rarely found in children older than 10 years. Age, stage, and biological features encountered in tumor cells are important prognostic factors and are used for risk stratification and treatment assignment.
Neuroblastoma can be subdivided into a biologically defined subset that has a very favorable prognosis (i.e., low-risk neuroblastoma) and another group that has a guarded prognosis (i.e., high-risk neuroblastoma). While neuroblastoma in infants with tumors that have favorable biology is highly curable, only 50% of children with high-risk neuroblastoma are alive at 5 years from diagnosis, at best.
A little more than 1 out of 3 neuroblastomas start in the adrenal glands. About 1 out of 4 begin in sympathetic nerve ganglia in the abdomen and the remaining start in sympathetic ganglia near the spine in the chest or neck, or in the pelvis. 90% of those diagnosed are under the age of 5, with a peak age of incidence of 2-3. Neuroblastoma etiology is unknown. Several genes are found to be associated with familial neuroblastoma.
“Neuroblastoma (NB) Epidemiology Insights, 2023” report provides historical as well as forecasted epidemiology of Neuroblastoma (NB) in the 7MM. Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Table of Content of the report –
1. Report Introduction
2. Snapshot of Total Prevalent or Incident cases by 7 MM.
3. Executive Summary – Key Findings.
4. Neuroblastoma (NB) Overview – Neuroblastoma (NB) Definition, Pathophysiology, Symptoms and Etiology.
5. Risk Factors Associated with Neuroblastoma (NB)
6. Disease Burden & Unmet Need in the Market
7. Epidemiology and Patient Populations
• Key Findings
• Key Sources used and Forecast Methodology
• Prevalent Cases and Incident Cases-2015-2025
• Prevalent & Incident Cases by Category-2015-2025
• Age-Specific Prevalent/ Incident Cases of Neuroblastoma (NB)
• Sex-Specific Prevalent/Incident Cases of Neuroblastoma (NB)
• Disease Type Specific Prevalent/Incident Cases of Neuroblastoma (NB)
8. Prevalent & Incident Cases by 7 MM-2015-2025 – Neuroblastoma (NB) Epidemiology of United States, UK, Germany, France, Spain, Italy and Japan.
9. Key Takeaways
10. Appendix
11. Report Methodology
12. Consulting Services
13. Disclaimer
14. About Us
Avail complete report of 40 pages @ https://www.diligentmarket.com/neuroblastoma-epidemiology-insights-to-2025-15334-p.php
Diligent Market also provides a report on pipeline insights, “Neuroblastoma (NB) -Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Neuroblastoma (NB). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Neuroblastoma (NB) by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.
The report provides a snapshot of the pipeline development for the Neuroblastoma (NB). It covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Neuroblastoma (NB). The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information. Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Neuroblastoma (NB) the report also covers the dormant and discontinued pipeline projects related to the Neuroblastoma (NB).
Check complete report @ https://www.diligentmarket.com/neuroblastoma-pipeline-insight-2017-14212-p.php with key players like Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Advanced Accelerator Applications SA, Alissa Pharma, Ampio Pharmaceuticals Inc, APAvadis Biotechnologies Srl, APEIRON Biologics AG, AstraZeneca Plc, Bayer AG, Bellicum Pharmaceuticals Inc, Bexion Pharmaceuticals LLC, BioLineRx Ltd, Biotec Pharmacon ASA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cancer Prevention Pharmaceuticals Inc, Cebiotex SL, and many more. mentioned in it.
Diligent Market also provides a complete combination of market insights, epidemiology and market forecast till 2023 in one report. According to Diligent Market, the forecasted patient population of Neuroblastoma for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Neuroblastoma 7MM market size is estimated to be USD XX by 2025
Report – “Neuroblastoma (NB)-Market Insights, Epidemiology and Market Forecast-2023” will help in developing business strategies by understanding the trends shaping and driving the Neuroblastoma (NB) market. It helps in organizing sales and marketing efforts by identifying the best opportunities for Neuroblastoma (NB) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. It helps in understanding the future market competition of Neuroblastoma (NB) therapies in the 7MM and Insightful review of the key market drivers and barriers. The report provides historical as well as forecasted epidemiology of Neuroblastoma (NB) in the 7MM. Report also gives regulatory scenario in major markets. The Report also covers the detailed historical and forecasted Neuroblastoma (NB) market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Complete report with description, table of content and list of figures @ https://www.diligentmarket.com/neuroblastoma-market-insights-epidemiology-and-market-forecast-2025-14887-p.php
For further information or queries, please contact the Sales Team, Diligent Market at sales@DiligentMarket.com / irfan@DiligentMarket.com or call us at +91 750–707-8687.
Contact Info:
Name: Irfan Tamboli
Organization: Diligent Market
Address: Pune
Phone: +91 750–707-8687.
For more information, please visit https://www.diligentmarket.com/
Source: MarketersMedia
Release ID: 246058
Copyright © 1999-2013 SproutNews.com
